Project Grant R01CA292091
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$598K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $704,563 to the Beckman Research Institute of the City of Hope to develop quantitative MRI tools and an automated prostate cancer tumor segmentation method. The key objectives are to: Build a quantitative MRI toolset including magnetic resonance fingerprinting, arterial spin labeling, and diffusion-weighted MRI to generate high-resolution quantitative maps linked...
This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of an artificial intelligence-based system for analyzing multiparametric magnetic resonance imaging (MRI) scans to detect prostate lesions. The awardee, Taurus Diagnostics, Inc., will create a novel prostate cancer diagnostic platform leveraging artificial intelligence image analysis for high sensitivity and specificity. Key objectives include developing methods to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $245,087 to the University of Delaware (UD) to develop an advanced AI-based model for interpreting prostate MRI scans. The key objectives are to: 1) Curate a comprehensive dataset of 300 public and 50 MRI scans from Memorial Sloan Kettering (MSK) with corresponding PIRADS radiologist reports; 2) Leverage GPT-4 to extract radiologist reasoning from the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $538,553 to the University of Miami to conduct longitudinal research on the use of multiparametric MRI and liquid biopsy markers to predict radiotherapy outcomes for patients with intermediate and high-risk prostate cancer. The key objectives of the research are to: 1) define the role of quantitative multiparametric MRI features in combination with circulating tumor...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a real-time functional imaging platform to detect and characterize prostate cancer aggressiveness. The $568,151 award, effective from February 3, 2025 to January 31, 2030, will enable the Regents of the University of Michigan to: Optimize biocompatible polyacrylamide hydrogel nanoscale probes (PAA NPs) for...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $185,171 Project Grant (CFDA 93.286: Discovery and Applied Research for Technological Innovations to Improve Human Health) to The Johns Hopkins University to develop and optimize novel polymeric contrast agents for magnetic resonance imaging (MRI) to detect prostate cancer and distinguish it from benign prostate hyperplasia. The research aims to optimize the physicochemical properties of these polymeric MRI...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports the development and validation of radiopathomic modeling techniques to improve the characterization and monitoring of glioma brain tumors. The $677,998 award to the Medical College of Wisconsin will enable external validation of radiopathomic mapping algorithms on datasets from multiple institutions, unification and refinement of the models, and a prospective...
This $680,433 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research at the University of California, San Francisco (UCSF) to improve prognostic estimation and elucidate the biological underpinnings of prostate cancer. The key objectives are to: 1) understand the relationships between established genomic tests and emerging pathology artificial intelligence (PAI) algorithms in predicting outcomes after...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop an innovative liquid biopsy approach using circulating tumor DNA (ctDNA) fragmentomics to monitor metastatic castration-resistant prostate cancer (mCRPC). The $680,453 award to the University of Wisconsin-Madison aims to: Determine if baseline ctDNA fragmentomics scores are prognostic biomarkers in mCRPC, Detect diverse androgen...